On Feb. 17, 2023, Moderna announced that Health Canada had authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 (SpikevaxBivalent Original/Omicron) in children and adolescents 6 to 17 years of age.

The authorizations are based on a 25 ﾵg booster dose for children ages 6 to 11 years old and a 50 ﾵg booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized COVID-19 vaccines or a previous booster.